Table 1.
Demographic and clinical characteristics of cases and controls among BNT162b2 and mRNA-1273 recipients who were considered in the primary test-negative analysis
| Characteristic | BNT162b2 case population |
BNT162b2 control population |
mRNA-1273 case population |
mRNA-1273 control population |
|---|---|---|---|---|
| 1+ positive symptomatic test after full vaccination | 1+ negative symptomatic test after full vaccination, sub-sampled | 1+ positive symptomatic test after full vaccination | 1+ negative symptomatic test after full vaccination, sub-sampled | |
| Number of individuals | 2,407 | 12,763 | 814 | 5,879 |
| Number of symptomatic tests | 2,407 | 13,668 | 814 | 6,294 |
| Age (years) | ||||
| Mean (SD) | 49.9 (16.1) | 51.1 (18.9) | 56.7 (17.9) | 58.6 (18.2) |
| 18–24 | 96 (4.0%) | 630 (4.9%) | 32 (3.9%) | 237 (4.0%) |
| 25–34 | 308 (12.8%) | 2,150 (16.8%) | 78 (9.6%) | 557 (9.5%) |
| 35–44 | 445 (18.5%) | 2,217 (17.4%) | 135 (16.6%) | 731 (12.4%) |
| 45–54 | 384 (16.0%) | 1,821 (14.3%) | 106 (13.0%) | 712 (12.1%) |
| 55–64 | 416 (17.3%) | 2,225 (17.4%) | 150 (18.4%) | 1,077 (18.3%) |
| 65–74 | 364 (15.1%) | 1,865 (14.6%) | 191 (23.5%) | 1,539 (26.2%) |
| 75–84 | 292 (12.1%) | 1,304 (10.2%) | 84 (10.3%) | 695 (11.8%) |
| 85+ | 102 (4.2%) | 551 (4.3%) | 38 (4.7%) | 331 (5.6%) |
| State of primary residence | ||||
| Arizona | 147 (6.1%) | 1,198 (9.4%) | 33 (4.1%) | 410 (7.0%) |
| Florida | 464 (19.3%) | 2,071 (16.2%) | 281 (34.5%) | 1,741 (29.6%) |
| Iowa | 6 (0.2%) | 6 (0.0%) | 2 (0.2%) | 3 (0.1%) |
| Minnesota | 1,052 (43.7%) | 6,020 (47.2%) | 342 (42.0%) | 2,611 (44.4%) |
| Wisconsin | 737 (30.6%) | 3,468 (27.2%) | 156 (19.2%) | 1,113 (18.9%) |
| Other | 1 (0.0%) | 1 (0.0%) | ||
|
Sex | ||||
| Female | 1,444 (60.0%) | 8,071 (63.2%) | 431 (52.9%) | 3,364 (57.2%) |
| Male | 963 (40.0%) | 4,691 (36.8%) | 383 (47.1%) | 2,514 (42.8%) |
| Unknown | 1 (0.0%) | 1 (0.0%) | ||
| Race | ||||
| Asian | 56 (2.3%) | 475 (3.7%) | 10 (1.2%) | 176 (3.0%) |
| Black/African American | 54 (2.2%) | 322 (2.5%) | 17 (2.1%) | 169 (2.9%) |
| Native American | 2 (0.1%) | 31 (0.2%) | 3 (0.4%) | 18 (0.3%) |
| Native Hawaiian/Pacific Islander | 2 (0.1%) | 9 (0.1%) | 2 (0.2%) | 1 (0.0%) |
| White | 2,227 (92.5%) | 11,501 (90.1%) | 744 (91.4%) | 5,354 (91.1%) |
| Other | 46 (1.9%) | 288 (2.3%) | 21 (2.6%) | 106 (1.8%) |
| Unknown | 20 (0.8%) | 137 (1.1%) | 17 (2.1%) | 55 (0.9%) |
| Ethnicity | ||||
| Hispanic or Latino | 85 (3.5%) | 459 (3.6%) | 40 (4.9%) | 236 (4.0%) |
| Not Hispanic or Latino | 2,284 (94.9%) | 12,017 (94.2%) | 744 (91.4%) | 5,535 (94.1%) |
| Unknown | 38 (1.6%) | 287 (2.2%) | 30 (3.7%) | 108 (1.8%) |
| Elixhauser Comorbidity Index | ||||
| 0 | 1,725 (71.7%) | 9,326 (73.1%) | 566 (69.5%) | 3,895 (66.3%) |
| 1–4 | 359 (14.9%) | 1,702 (13.3%) | 125 (15.4%) | 875 (14.9%) |
| 5–9 | 216 (9.0%) | 1,133 (8.9%) | 93 (11.4%) | 695 (11.8%) |
| 10+ | 107 (4.4%) | 602 (4.7%) | 30 (3.7%) | 414 (7.0%) |
| Number of PCR tests prior to first dose | ||||
| 0 | 1,108 (46.0%) | 4,680 (36.7%) | 356 (43.7%) | 2,277 (38.7%) |
| 1 | 569 (23.6%) | 3,030 (23.7%) | 192 (23.6%) | 1,407 (23.9%) |
| 2+ | 730 (30.3%) | 5,053 (39.6%) | 266 (32.7%) | 2,195 (37.3%) |
| First dose vaccine site | ||||
| Arizona | 58 (2.4%) | 450 (3.5%) | 18 (2.2%) | 218 (3.7%) |
| Florida | 350 (14.5%) | 1,661 (13.0%) | 226 (27.8%) | 1,448 (24.6%) |
| Mayo Clinic Health System | 953 (39.6%) | 4,010 (31.4%) | 158 (19.4%) | 1,249 (21.2%) |
| Rochester (Minnesota) | 526 (21.9%) | 3,883 (30.4%) | 372 (45.7%) | 2,339 (39.8%) |
| Other/not recorded | 520 (21.6%) | 2,759 (21.6%) | 40 (4.9%) | 625 (10.6%) |
| Dates of full vaccination | ||||
| Earliest | Jan 20 | Jan 18 | Feb 8 | Feb 1 |
| 25th % | Feb 17 | Feb 15 | Feb 25 | Mar 2 |
| Median | Mar 17 | Mar 15 | Mar 25 | Mar 25 |
| 75th % | Apr 22 | Apr 22 | Apr 21 | Apr 21 |
| Latest | Sep 2 | Aug 30 | Aug 1 | Aug 30 |
| Days between full vaccination and test | ||||
| Minimum | 0 | 0 | 1 | 0 |
| 25th % | 113 | 111 | 120 | 114 |
| Median | 149 | 145 | 147 | 142 |
| 75th % | 184 | 182 | 167 | 167 |
| Maximum | 238 | 243 | 221 | 221 |
Cases were defined as the first positive symptomatic test after full vaccination for a given individual, and controls were defined as negative symptomatic tests after full vaccination. Individuals can thus contribute only one case but multiple controls. A negative test is only considered if the individual had no prior positive tests at the time of testing. Controls were sub-sampled to avoid counting multiple negative tests from a single symptomatic illness and to limit the number of negative tests contributed by a single individual over the study duration. Characteristics of the underlying populations from which cases and controls are derived are shown in Tables S1 (BNT162b2) and S2 (mRNA-1273).